COLL · XBRL financial data

Collegium Pharmaceutical financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (COLL's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	137	150	145	145	159	182	178	188	209	205	194	200
Cost of goods and services sold	56	55	53	54	63	84	80	80	80	77	76	90
Gross profit	80	95	91	91	97	98	97	108	129	128	117	110
Research and development	—	year only	—	—	—	year only	—	—	—	—	—	—
Selling, general and administrative	35	33	42	43	62	63	76	74	67	68	86	107
Total operating expenses	35	33	42	43	62	60	76	73	67	68	86	107
Operating income (loss)	45	62	49	47	35	38	22	35	62	61	31	4
Interest income	—	—	4	4	3	—	2	2	3	—	—	—
Interest expense	21	19	17	16	18	23	21	20	22	19	16	20
Income tax expense (benefit)	8	15	9	9	6	5	1	5	12	12	4	2
Net income (loss)	21	32	28	20	9	13	2	12	32	17	14	(15)
Earnings per share, basic USD per share	0.61	0.99	0.86	0.60	0.29	0.39	0.08	0.38	1.00	0.54	0.45	(0.46)
Earnings per share, diluted USD per share	0.53	0.82	0.71	0.52	0.27	0.36	0.07	0.34	0.84	0.46	0.40	(0.46)
Weighted average shares, basic millions of shares	34	32	32	32	32	32	32	32	32	32	32	32
Weighted average shares, diluted millions of shares	42	41	41	40	40	40	33	39	39	40	40	32

Fiscal quarters (COLL's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	259	239	229	173	39	71	96	117	150	231	269	129
Marketable securities	46	72	89	99	81	92	102	105	136	155	153	0
Accounts receivable	182	180	175	184	228	229	229	213	234	211	229	285
Inventory	34	32	31	28	38	36	37	38	38	41	43	113
Prepaid and other current assets	17	15	15	27	32	30	44	56	36	33	33	60
Total current assets	537	538	539	510	444	482	528	549	614	691	746	608
Property and equipment, net	17	16	15	15	15	14	14	13	12	12	12	11
Right-of-use asset	6	6	6	6	6	6	6	5	4	4	4	4
Goodwill	134	134	134	134	146	162	151	148	146	146	146	190
Total assets	1,178	1,143	1,114	1,053	1,635	1,664	1,631	1,593	1,607	1,657	1,652	2,136
Accounts payable	4	9	6	2	3	4	18	11	8	11	7	9
Accrued liabilities	32	38	38	39	48	72	54	59	51	62	58	71
Total current liabilities	465	458	446	462	459	510	487	465	453	440	435	590
Lease liability, non-current	6	6	6	6	6	6	5	5	5	4	4	3
Total liabilities	999	948	892	837	1,401	1,435	1,397	1,360	1,333	1,355	1,340	1,824
Accumulated deficit	(265)	(233)	(205)	(186)	(177)	(164)	(162)	(150)	(118)	(101)	(87)	(102)
Total stockholders' equity	179	195	222	217	234	229	234	232	275	302	312	312
Total liabilities and equity	1,178	1,143	1,114	1,053	1,635	1,664	1,631	1,593	1,607	1,657	1,652	2,136
Common shares outstanding (cover page) millions of shares	33	32	33	32	32	31	32	32	32	32	32	33

Fiscal quarters (COLL's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	21	32	28	20	9	13	2	12	32	17	14	(15)
Stock-based compensation	7*	7*	7	10*	7*	8*	12	11*	10*	10*	11	14*
Net cash from operating activities	74*	73*	62	67*	(9)*	85*	55	72*	78*	123*	57	71*
Purchases of property and equipment	0*	0*	1	0*	0*	1*	1	0*	0*	1*	0	0*
Net cash from investing activities	(4)*	(25)*	(18)	(9)*	(249)*	(12)*	(10)	(3)*	(31)*	(20)*	2	(503)*
Share repurchases	—	25*	—	—	0*	25*	—	25	0*	0*	—	0
Net cash from financing activities	(95)*	(68)*	(54)	(114)*	149*	(41)*	(25)	(48)*	(15)*	(22)*	(21)	292*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Collegium Pharmaceutical	129	200	71*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Ardelyx	46	128	2.2*	251.4M	—	Q3 FY26 10-QSep 30, 2026
Viridian Therapeutics	173	26	(93)*	113.6M	9.0 quarters	Q3 FY26 10-QSep 30, 2026
CorMedix	257	102	86*	77.9M	—	Q2 FY26 10-QJun 30, 2026
Akebia Therapeutics	156	49	3.5*	277.1M	—	Q2 FY26 10-QJun 30, 2026
Neogen	172	223	13	218.3M	—	Q1 FY27 10-QAug 31, 2026
Intellia Therapeutics	106	7.7	(83)*	140.1M	5.3 quarters	Q2 FY26 10-QJun 30, 2026
Geron	63	57	(16)*	642.5M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	46	84	46*	134.0M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.